The application of metal oxides in industries has been strengthened by the emergence of perovskite-based materials like bismuth titanates (Bi4Ti3O12 -BTO). They display new functionalities coupled with several mechanisms like doping engineering, crystalline and microstructure. Recently, the research on BTO with other doping elements has moved toward enhanced microstructural applications. This article mainly focuses on recent developments in the fabrication methods, crystal structure and microstructural analysis of BTO materials with doping elements. The excellent microstructure, easy synthesis methods, high chemical stability, good optical efficiency, and perfect doping made this material attractive. The crystal structure transition is analyzed. This review contemplates the current research on various BTO-based materials. A detailed discussion on grain size density measurements is given. This work concludes by establishing the future perspectives, challenges and present industrial applications of BTO.

• Klíčová slova
• Aurivillius, Bi(4)Ti(3)O(12), Crystal structure, Doping, Microstructure, Phase transition,
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

BACKGROUND: The efficacy of paclitaxel-eluting balloon catheters (PEB) and drug-eluting stents for treatment of bare-metal stent restenosis (BMS-ISR) have been demonstrated in several studies with follow-up times of 9 to 12 months; however, the long-term outcomes of ISR treatment are less defined. OBJECTIVES: We aimed to compare the long-term efficacy of PEB and everolimus-eluting stents (EES) for the treatment of BMS-ISR. METHODS: We analyzed 3-year clinical follow-up data from patients included in the TIS randomized clinical study. A total of 136 patients with BMS-ISR were allocated to receive treatment with either PEB or EES (68 patients with 74 ISR lesions per group). RESULTS: The PEB and EES groups did not significantly differ in major adverse cardiac events-free survival (MACE; P = .211; including individual events: CV death: P = .622; myocardial infarction: P = .650 or target vessel revascularization: P = .286) at 3-year clinical follow-up. No event-free survival differences were found between the groups regarding overall mortality (P = .818), definite stent thrombosis (P = .165) or the second MACE (P = .270). CONCLUSIONS: At the 3-year follow-up, no significant differences in clinical outcomes were found between iopromide-coated PEB and EES for the treatment of BMS-ISR. (ClinicalTrials.gov; https://clinicaltrials.gov; NCT01735825).

• Klíčová slova
• everolimus-eluting stent, in-stent restenosis, paclitaxel-eluting balloon,
• MeSH
• balónková koronární angioplastika škodlivé účinky   přístrojové vybavení   mortalita   MeSH
• biokompatibilní potahované materiály * MeSH
• časové faktory MeSH
• doba přežití bez progrese choroby MeSH
• everolimus aplikace a dávkování   škodlivé účinky   MeSH
• kardiovaskulární látky aplikace a dávkování   škodlivé účinky   MeSH
• koronární angioplastika škodlivé účinky   přístrojové vybavení   mortalita   MeSH
• koronární restenóza diagnostické zobrazování   etiologie   mortalita   terapie   MeSH
• kovy * MeSH
• lidé středního věku MeSH
• lidé MeSH
• opakovaná terapie MeSH
• paclitaxel aplikace a dávkování   škodlivé účinky   MeSH
• prospektivní studie MeSH
• protézy - design MeSH
• rizikové faktory MeSH
• senioři MeSH
• srdeční katétry * MeSH
• stenty uvolňující léky * MeSH
• stenty * MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH
• Názvy látek
• biokompatibilní potahované materiály * MeSH
• everolimus MeSH
• kardiovaskulární látky MeSH
• kovy * MeSH
• paclitaxel MeSH

BACKGROUND: Response to neoadjuvant chemotherapy is associated with improved outcomes for patients with triple negative breast cancer (TNBC). Patients with residual disease are at increased risk of relapse and death from breast cancer. In this retrospective study, we aimed to evaluate the efficacy and safety of cisplatin added to standard neoadjuvant chemotherapy for locally advanced TNBC. MATERIALS AND METHODS: All TNBC treated with neoadjuvant cisplatin 60mg/m2 once in 3 weeks with weekly paclitaxel for 12 weeks, following 8 weeks of dose-dense epirubicin 90mg/m2 or doxorubicin 60mg/m2 with cyclophosphamide 600mg/m2 were analyzed retrospectively. The data related to pathological complete response, adherence to planned therapy, disease-free survival and overall survival were collected. RESULTS: Eighty-three patients were included, of whom 80% had stage III disease. Pathological complete response in both breast (T0/Tis) and axilla (N0) was observed in 48.1% of patients. Miller Payne grade 5 pathological response in the breast was seen in 61% of patients. Good partial responses (Miller Payne grades 3,4) were observed in 32.5% of patients. The remaining 6.5% were poor responders. Seventy-seven patients underwent surgery. The disease-free survival at 1 and 3 years for those who had a pathological complete response was 96.7% and 77.6%, respectively, and 92.3% and 62.7% for those who did not, respectively. The predominant adverse events were hematological, with anemia being the most common one. CONCLUSION: The addition of cisplatin to neoadjuvant chemotherapy with anthracycline and taxane in TNBC was tolerable and produced a high rate of pathological complete response. Cisplatin added to standard chemotherapy in patients with locally advanced TNBC could improve clinical outcomes.

• Klíčová slova
• cisplatin, neoadjuvant chemotherapy, pathological complete response, residual cancer burden, triple negative breast cancer,
• MeSH
• anemie chemicky indukované   MeSH
• cisplatina aplikace a dávkování   škodlivé účinky   MeSH
• cyklofosfamid aplikace a dávkování   škodlivé účinky   MeSH
• dospělí MeSH
• doxorubicin aplikace a dávkování   škodlivé účinky   MeSH
• epirubicin aplikace a dávkování   škodlivé účinky   MeSH
• kombinovaná farmakoterapie MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• neoadjuvantní terapie MeSH
• paclitaxel aplikace a dávkování   škodlivé účinky   MeSH
• protinádorové látky aplikace a dávkování   škodlivé účinky   MeSH
• retrospektivní studie MeSH
• staging nádorů MeSH
• triple-negativní karcinom prsu farmakoterapie   patologie   chirurgie   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• cisplatina MeSH
• cyklofosfamid MeSH
• doxorubicin MeSH
• epirubicin MeSH
• paclitaxel MeSH
• protinádorové látky MeSH